Cat. #151438
Anti-HLADR [BU43]
Cat. #: 151438
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: Human Leukocyte Antigen-DR locus (HLA-DR) associated invariant chain (CD74)
Class: Monoclonal
Application: FACS ; IHC ; IP ; RIA
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Roy Jefferis
Institute: University of Birmingham
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-HLADR [BU43]
- Alternate name: CD74 Molecule; HLA-DR Antigens-Associated Invariant Chain; Gamma Chain Of Class II Antigens; Ia-Associated Invariant Chain; MHC HLA-DR Gamma Chain; DHLAG; P33; CD74 Antigen; Ia-GAMMA; HLADG
- Research fields: Immunology
- Clone: BU43
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Strain: Balb/c
- Reactivity: Human
- Host: Mouse
- Application: FACS ; IHC ; IP ; RIA
- Description: HLA-DR-associated invariant chain (CD74) plays a role in antigen presentation. In addition to its expression on antigen-presenting cells, CD74 is expressed by carcinomas of renal, lung, gastric, and thymic origin and by certain sarcomas. The restricted expression of CD74 by normal tissues and its very rapid internalization make CD74 an attractive therapeutic target for both cancer and immunologic diseases. It has also been shown to have value as a gastric carcinoma marker.
- Immunogen: HFB1 plasmacytoid cell line
- Isotype: IgM
- Myeloma used: NS0
Target Details
- Target: Human Leukocyte Antigen-DR locus (HLA-DR) associated invariant chain (CD74)
- Target background: HLA-DR-associated invariant chain (CD74) plays a role in antigen presentation. In addition to its expression on antigen-presenting cells, CD74 is expressed by carcinomas of renal, lung, gastric, and thymic origin and by certain sarcomas. The restricted expression of CD74 by normal tissues and its very rapid internalization make CD74 an attractive therapeutic target for both cancer and immunologic diseases. It has also been shown to have value as a gastric carcinoma marker.
Applications
- Application: FACS ; IHC ; IP ; RIA
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
References
- Gregers et al. 2003. Int Immunol. 15(11):1291-9. PMID: 14565927.
- MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation.
- Nordeng et al. 2002. Mol Biol Cell. 13(6):1846-56. PMID: 12058053.
- The cytoplasmic tail of invariant chain regulates endosome fusion and morphology.
- Nordeng et al. 1999. J Biol Chem. 274(30):21139-48. PMID: 10409667.
- Overexpression of proteins containing tyrosine- or leucine-based sorting signals affects transferrin receptor trafficking.
- Moldenhauer et al. 1999. Immunology. 96(3):473-84. PMID: 10233730.
- Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments.
- Rudy et al. 1997. J Immunol. 158(5):2116-25. PMID: 9036956.
- The nonpolymorphic MHC class II isotype, HLA-DQA2, is expressed on the surface of B lymphoblastoid cells.
- Koch et al. 1991. J Immunol. 147(8):2643-51. PMID: 1918985.
- Rapid intracellular pathway gives rise to cell surface expression of the MHC class II-associated invariant chain (CD74).
- Wraight et al. 1990. J Biol Chem. 265(10):5787-92. PMID: 1690714.
- Human major histocompatibility complex class II invariant chain is expressed on the cell surface.